- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03718026
The Reliability, Validity, and Responsiveness of the Timed 360° Turn Test in Patients With Multiple Sclerosis
November 19, 2018 updated by: Fatih Söke, Gazi University
The Reliability, Validity, and Responsiveness of the Timed 360° Turn Test Test in Patients With Multiple Sclerosis
The aim of the study is to investigate reliability, validity, and responsiveness of the timed 360° turn test in patients with Multiple Sclerosis.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
At baseline, the timed 360° turn test, Berg Balance Scale, Timed Up and Go test, Functional Reach Test, Four Square Step Test, and One-legged Stance Test is applied to the Multiple Sclerosis group.
The timed 360° turn test is repeated after seven days from the first application in patients with Multiple Sclerosis.
Healthy controls are going to perform only the timed 360° turn test.
Study Type
Observational
Enrollment (Actual)
95
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Ankara, Turkey, 06560
- Fatih Söke
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 65 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Sampling Method
Probability Sample
Study Population
Patients with Multiple Sclerosis who apply to Gazi University, Department of Physiotherapy and Rehabilitation will be invited to this study.
Description
Inclusion Criteria:
- at least 18 years,
- neurologist-diagnosed Multiple Sclerosis,
- Expanded Disability Status Scale (EDSS) score < 7,
- able to walk 20 m with or without aids,
- no MS exacerbation within the last 2 months,
- use of stable medication in the last 2 months.
Exclusion Criteria:
- other neurologic disorder,
- Pregnancy,
- orhopedic problems affecting gait and stance,
- visual, auditory, orientational problems that could affect study results,
- Cardiovascular, pulmonary, and humoral disease.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Observational Models: Case-Control
- Time Perspectives: Cross-Sectional
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
|---|---|
|
Patients with Multiple Sclerosis
|
Other Names:
|
|
Healthy Controls
-The timed 360° turn test
|
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
The timed 360° turn test
Time Frame: 1 minute
|
The timed 360° turn test evaluates turning ability.
Higher durations indicate worse turning performance.
|
1 minute
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Berg Balance Scale
Time Frame: 10 minutes
|
Berg Balance Scale assesses functional balance.
It consists of 14 functional tasks rated on a 5-point scale ranging from 0 to 4. The maximum score is 56 points.
Higher scores indicate better functional balance.
|
10 minutes
|
|
Timed Up and Go test
Time Frame: 1 minute
|
Timed Up and Go test evaluates functional mobility.
Higher durations indicate worse functional mobility.
|
1 minute
|
|
Functional Reach Test
Time Frame: 1 minute
|
Functional Reach Test is used to evaluate limits of stability.
Higher distances indicate better limits of stability.
|
1 minute
|
|
Four Square Step Test
Time Frame: 1 minute
|
Four Square Step Test is used to assess dynamic balance.
Higher durations indicate worse dynamic balance.
|
1 minute
|
|
One Leg Stance Test
Time Frame: 3 minutes
|
One Leg Stance Test evaluates postural stability.
Higher durations indicate better postural stability.
|
3 minutes
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Fatih Söke, Gazi University
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
General Publications
- Adusumilli G, Lancia S, Levasseur VA, Amblee V, Orchard M, Wagner JM, Naismith RT. Turning is an important marker of balance confidence and walking limitation in persons with multiple sclerosis. PLoS One. 2018 Jun 7;13(6):e0198178. doi: 10.1371/journal.pone.0198178. eCollection 2018.
- Spain RI, St George RJ, Salarian A, Mancini M, Wagner JM, Horak FB, Bourdette D. Body-worn motion sensors detect balance and gait deficits in people with multiple sclerosis who have normal walking speed. Gait Posture. 2012 Apr;35(4):573-8. doi: 10.1016/j.gaitpost.2011.11.026. Epub 2012 Jan 25.
- Gunn H, Creanor S, Haas B, Marsden J, Freeman J. Frequency, characteristics, and consequences of falls in multiple sclerosis: findings from a cohort study. Arch Phys Med Rehabil. 2014 Mar;95(3):538-45. doi: 10.1016/j.apmr.2013.08.244. Epub 2013 Sep 18.
- Cameron MH, Asano M, Bourdette D, Finlayson ML. People with multiple sclerosis use many fall prevention strategies but still fall frequently. Arch Phys Med Rehabil. 2013 Aug;94(8):1562-6. doi: 10.1016/j.apmr.2013.01.021. Epub 2013 Feb 4.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
October 24, 2018
Primary Completion (Actual)
November 16, 2018
Study Completion (Actual)
November 19, 2018
Study Registration Dates
First Submitted
October 22, 2018
First Submitted That Met QC Criteria
October 22, 2018
First Posted (Actual)
October 24, 2018
Study Record Updates
Last Update Posted (Actual)
November 21, 2018
Last Update Submitted That Met QC Criteria
November 19, 2018
Last Verified
November 1, 2018
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 438
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
No
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Multiple Sclerosis, Relapsing-Remitting
-
BiogenWithdrawnRelapsing-Remitting Multiple Sclerosis | Relapsing Forms of Multiple Sclerosis
-
Cabaletta BioNot yet recruitingProgressive Multiple Sclerosis | Multiple Sclerosis | Multiple Sclerosis (Relapsing Remitting) | Relapsing Multiple Sclerosis (RMS) | Progressive Multiple Sclerosis (PMS) | Multiple Sclerosis (MS) - Relapsing-remitting | Multiple Sclerosis - Relapsing Remitting
-
Hoffmann-La RochePPD Development, LPActive, not recruitingRelapsing-Remitting Multiple SclerosisUnited States, Spain, Canada, Portugal, India, United Kingdom, Belgium, France, Brazil, Austria, Germany, Hungary, Estonia, Poland, Mexico, Australia, Italy, Ukraine, Serbia, Latvia, Morocco, Argentina, Switzerland, Greece, Romania
-
Bristol-Myers SquibbActive, not recruitingRelapsing-remitting Multiple Sclerosis (RRMS)Spain
-
BiogenWithdrawn
-
BiogenAbbVieTerminatedMultiple Sclerosis | Relapsing-Remitting Multiple SclerosisUnited States, Denmark, Italy, United Kingdom, Czechia, Canada, Hungary, Spain, Australia, Israel, Georgia, Serbia, Russian Federation, Ukraine, India, Poland, Brazil, France, Argentina, Germany, Greece, Ireland, Mexico, Moldova, Republic... and more
-
EMD SeronoPfizerCompletedRelapsing-remitting Multiple SclerosisUnited States, United Kingdom, Argentina, Austria, Brazil, France, Germany, Italy, Netherlands, Russian Federation, Spain, Switzerland
-
National Institute of Allergy and Infectious Diseases...Immune Tolerance Network (ITN)CompletedRelapsing-Remitting Multiple SclerosisUnited States
-
BiogenTerminatedRelapsing-Remitting Multiple SclerosisUnited States, Spain, Germany, Australia, Sweden, Czechia, France, Italy, United Kingdom
-
Novartis PharmaceuticalsWithdrawnMultiple Sclerosis (Relapsing Remitting)
Clinical Trials on The timed 360° turn test
-
Kahramanmaras Sutcu Imam UniversityCompletedCerebral Palsy | Gait, Spastic | Gait Disorders in Children | Diplegic Cerebral Palsy | Hemiplegic Cerebral PalsyTurkey
-
Gazi UniversityCompletedMultiple SclerosisTurkey
-
Gazi UniversityCompleted
-
Clalit Health ServicesUnknownElderly | Falls | Postural BalanceIsrael
-
Uskudar State HospitalRecruitingMultiple SclerosisTurkey
-
Centre d'Investigation Clinique et Technologique...Completed
-
Istinye UniversityCompletedStroke | Tele-assessment | The Timed Up & Go Test | 30second Chair-Stand TestTurkey
-
University of HaifaCompletedHealthy Aging | Gender | Swallowing Disorder
-
Istanbul University - Cerrahpasa (IUC)CompletedMultiple Sclerosis | Gait Disorders, Neurologic | Upper Extremity ProblemTurkey
-
Afyonkarahisar Health Sciences UniversityRecruiting